Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Enliven Therapeutics Inc (NASDAQ: ELVN) closed the day trading at $17.17 up 1.84% from the previous closing price of $16.86. In other words, the price has increased by $1.84 from its previous closing price. On the day, 1.28 million shares were traded. ELVN stock price reached its highest trading level at $17.44 during the session, while it also had its lowest trading level at $16.77.
Ratios:
For a better understanding of ELVN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.95 and its Current Ratio is at 32.95. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42.
On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 08 ’25 when Patel Anish sold 6,663 shares for $21.02 per share. The transaction valued at 140,073 led to the insider holds 263,311 shares of the business.
Patel Anish bought 6,663 shares of ELVN for $145,320 on Dec 08 ’25. On Nov 19 ’25, another insider, Lyssikatos Joseph P, who serves as the CHIEF SCIENTIFIC OFFICER of the company, sold 12,500 shares for $22.33 each. As a result, the insider received 279,155 and left with 902,688 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 1018993408 and an Enterprise Value of 541918464.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.41, which has changed by -0.3087331 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $25.37, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is -17.03%, while the 200-Day Moving Average is calculated to be -14.04%.
Shares Statistics:
Over the past 3-months, ELVN traded about 602.99K shares per day on average, while over the past 10 days, ELVN traded about 794090 shares per day. A total of 59.26M shares are outstanding, with a floating share count of 43.29M. Insiders hold about 27.07% of the company’s shares, while institutions hold 77.97% stake in the company. Shares short for ELVN as of 1764288000 were 7996827 with a Short Ratio of 13.26, compared to 1761868800 on 7782638. Therefore, it implies a Short% of Shares Outstanding of 7996827 and a Short% of Float of 19.18.
Earnings Estimates
The stock of Enliven Therapeutics Inc (ELVN) is currently in the spotlight, with 1 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.36 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.96 and -$1.96 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.98, with 7.0 analysts recommending between -$1.55 and -$2.39.
